Esperion Therapeutics’ (ESPR) CEO Tim Mayleben on Q1 2015 Results … – Seeking Alpha

Esperion Therapeutics’ (ESPR) CEO Tim Mayleben on Q1 2015 Results
Seeking Alpha
We currently have 22.5 million shares of common stock outstanding with another 2.5 million to be issued upon the exercise of options and warrants. Looking forward we estimate cash used in operating expenses for the full year 2015 to be approximately

and more

…read more

Scroll to Top